Phenotypes Associated with This Genotype

Genotype
MGI:4837876

• Allelic Composition: Tg(Myh6-tTA)6Smbf/0; Tg(tetO-EDN1,-lacZ)9Mhus/0
• Genetic Background: involves: C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:131245 )

• within 8 weeks of doxycycline withdrawal more than half of mice die

• however, mice fed doxycycline exhibit normal survival

prenatal lethality, incomplete penetrance ( J:131245 )

• fewer than expected mice are generated indicating fetal loss

• however, treatment with doxycycline restores normal survival

cardiovascular system

cardiovascular system phenotype ( J:131245 )

N • after doxycycline withdrawal, mice do not exhibit bradyarrhythmias or tachyarrhythmias

liver vascular congestion ( J:131245 )

• after doxycycline withdrawal

pulmonary vascular congestion ( J:131245 )

• after doxycycline withdrawal

abnormal myocardial fiber morphology ( J:131245 )

• after doxycycline withdrawal, cardiomyocytes contain vesiculated nuclei unlike in wild-type cells

increased myocardial fiber size ( J:131245 )

• after doxycycline withdrawal

cardiac muscle necrosis ( J:131245 )

• after doxycycline withdrawal

abnormal ventricle endocardium morphology ( J:131245 )

• after doxycycline withdrawal, left ventricular endocardial circumference is increased compared to in wild-type mice

increased heart weight ( J:131245 )

• after doxycycline withdrawal

cardiac fibrosis ( J:131245 )

• mild after doxycycline withdrawal

decreased left ventricle systolic pressure ( J:131245 )

• 5 weeks after doxycycline withdrawal

prolonged P wave ( J:131245 )

• after doxycycline withdrawal

prolonged QRS complex duration ( J:131245 )

• lengthened progressively over time after doxycycline withdrawal

decreased systemic arterial systolic blood pressure ( J:131245 )

• 5 weeks after doxycycline withdrawal

heart inflammation ( J:131245 )

• after doxycycline withdrawal

behavior/neurological

hunched posture ( J:131245 )

• 5 weeks after doxycycline withdrawal

decreased locomotor activity ( J:131245 )

• 5 weeks after doxycycline withdrawal

respiratory system

pulmonary vascular congestion ( J:131245 )

• after doxycycline withdrawal

respiratory distress ( J:131245 )

• 5 weeks after doxycycline withdrawal

liver/biliary system

liver vascular congestion ( J:131245 )

• after doxycycline withdrawal

muscle

abnormal myocardial fiber morphology ( J:131245 )

• after doxycycline withdrawal, cardiomyocytes contain vesiculated nuclei unlike in wild-type cells

increased myocardial fiber size ( J:131245 )

• after doxycycline withdrawal

cardiac muscle necrosis ( J:131245 )

• after doxycycline withdrawal

immune system

heart inflammation ( J:131245 )

• after doxycycline withdrawal

growth/size/body

increased heart weight ( J:131245 )

• after doxycycline withdrawal